Kyowa Kirin Co., Ltd.: Lymphoma trials
The registry lists 13 Lymphoma studies with Kyowa Kirin Co., Ltd. as lead sponsor. 2 are open to participants now and 6 have results posted.
Phase 1 4Phase 2 8Phase 3 1No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin LymphomaRecruitingNCT07192471Phase 1
- Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With MogamulizumabRecruitingNCT04014374
- Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCLCompletedNCT01728805Phase 3Results posted
- KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)CompletedNCT01626664Phase 2Results posted
- Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001CompletedNCT01226472Phase 2Results posted
- Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphomaCompletedNCT00920790Phase 2Results posted
- Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell LymphomaCompletedNCT00888927Phase 1/2Results posted
- Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCLCompletedNCT00355472Phase 1Results posted
- A Study of KRN125 in Patients With Multiple Myeloma and Malignant LymphomaCompletedNCT05007652Phase 2
- Mogamulizumab Q4week Dosing in Participants With R/R CTCLActive, not recruitingNCT04745234Phase 2
- Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)CompletedNCT01611142Phase 2
- Study of KW-0761 in Subjects With CCR4-positive Peripheral T/NK-cell LymphomaCompletedNCT01192984Phase 2
- A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's LymphomaCompletedNCT00457782Phase 1